# Phase 4 Final Audit & Closure Report — `fusion_v1`

**Audit Date**: July 26, 2026  
**Scope**: Final formal closure audit of Phase 4 Multimodal Fusion Engine (`fusion_v1`). Verifies Out-Of-Fold (OOF) generation integrity, test-set isolation, 7-pathway metric reproducibility, modality attribution methodology, calibration/thresholds, adaptive routing, and research conclusions.

---

## 🏛️ EXECUTIVE SUMMARY & RECOMMENDATION

| Audit Section | Verification Status | Key Audit Finding |
|---|---|---|
| **1. OOF Stacking & Leakage** | **100% PASSED ✓** | Generated via 5-Fold Stratified K-Fold CV on 14,000 Training patients. Zero sample leakage. |
| **2. Test-Set Isolation** | **100% PASSED ✓** | 3,000-patient Test set used strictly for final evaluation after models/calibration/thresholds were frozen. |
| **3. 7-Pathway Reproducibility** | **100% PASSED ✓** | All 7 pathways (`C`, `W`, `G`, `C+W`, `C+G`, `W+G`, `C+W+G`) reproduced exact reported test metrics. |
| **4. Modality Attribution** | **100% PASSED ✓** | Mathematically defined as relative absolute L2 Logistic Regression coefficient decision weights normalized to 100%. |
| **5. Calibration & Thresholds** | **100% PASSED ✓** | Platt sigmoid calibrators and disease thresholds tuned on Validation fold (`Split == 'val'`) only. |
| **6. Adaptive Routing** | **100% PASSED ✓** | IMDIE router correctly routes all 7 missing-modality combinations with 0 zero-filling or data fabrication. |
| **7. Final Artifact Integrity** | **100% PASSED ✓** | All 7 meta-learners, calibrators, thresholds, target order, and metadata frozen in `fusion_v1/`. |

### 🎯 Final Recommendation: **GO FOR PHASE 5 MEDICAL RAG & PLATFORM UI** (Awaiting User Approval)

---

## 🔁 1. OOF STACKING & LEAKAGE VERIFICATION

### Methodology & Fold Construction
To prevent stacking data leakage, out-of-fold probability predictions were generated using **5-Fold Stratified Cross-Validation** on the 14,000-patient Training split (`Split == 'train'`).

```txt
• Population: 14,000 Patients (Split == 'train')
• Fold Splitter: StratifiedKFold(n_splits=5, shuffle=True, random_state=42)
• Fold Size: 11,200 Fit Patients / 2,800 Out-of-Fold Validation Patients per fold
```

### Leakage Audit Checklist:
1. **Fold-Specific Expert Training**: For every patient $i \in \{1, \dots, 14000\}$, the expert probability features $P_{\text{OOF}}(i)$ were predicted by a fold-specific model instance fitted strictly on the other 4 folds. The fold containing patient $i$ was excluded during model fitting.
2. **Patient_ID Alignment**: Patient_ID alignment was verified 100% identical across Clinical, Wearable, and Gut datasets prior to matrix concatenation.
3. **Fold-Enclosed Preprocessing**: `ExpertPreprocessor` was instantiated and fitted inside each CV loop on that fold's training split only.
4. **Test Set Separation**: The 3,000-patient Test set (`Split == 'test'`) and 3,000-patient Validation set (`Split == 'val'`) were NEVER included in the OOF CV loop.
5. **No Frozen Full-Training Overwrite**: Predictions from the full-train frozen Phase 3 experts (`clinical_v1`, `wearable_v1`, `gut_v1`) were NOT used as training features for the fusion meta-learners.

---

## 🔒 2. TEST-SET ISOLATION AUDIT

The **3,000-patient Test Set** (`Split == 'test'`) was kept completely untouched throughout Phase 4 development:
- **Meta-learner Architecture Selection** (Logistic Regression vs. XGBoost) was performed on Validation selection scores ($0.5 \cdot \text{ROC-AUC} + 0.5 \cdot \text{PR-AUC}$).
- **Probability Calibrators** (Platt Sigmoid) were fitted strictly on Validation probabilities (`Split == 'val'`).
- **Classification Thresholds** ($T_d \in [0.10, 0.90]$) were tuned strictly on Validation probabilities (`Split == 'val'`).
- **Test Set Evaluation** was executed exactly ONCE after all models, calibrators, and thresholds were frozen.

---

## 📊 3. 7-PATHWAY METRICS REPRODUCIBILITY

Inference was run through `FusionInferenceEngine` to reproduce all test set metrics across the 7 modality pathways.

### Master Comparative Benchmark Matrix (3,000-Patient Test Set)

| Pathway Key | Active Modalities | Selected Meta-Learner | Macro F1 | Micro F1 | Hamming Loss | Mean Brier Score | Status vs Reported |
|---|---|---|---|---|---|---|---|
| **C** | Clinical Only | Logistic Regression | **0.9602** | 0.9718 | 0.0107 | 0.0097 | EXACT MATCH ✓ |
| **W** | Wearable Only | Logistic Regression | **0.8300** | 0.8305 | 0.0637 | 0.0522 | EXACT MATCH ✓ |
| **G** | Gut Only | XGBoost | **0.6640** | 0.6686 | 0.1487 | 0.0931 | EXACT MATCH ✓ |
| **C+W** | Clinical + Wearable | Logistic Regression | **0.9599** | 0.9716 | 0.0107 | 0.0096 | EXACT MATCH ✓ |
| **C+G** | Clinical + Gut | Logistic Regression | **0.9593** | 0.9709 | 0.0110 | 0.0096 | EXACT MATCH ✓ |
| **W+G** | Wearable + Gut | **XGBoost** | **0.8405** | **0.8453** | **0.0590** | **0.0458** | EXACT MATCH ✓ |
| **C+W+G** | Full Tri-Modal | Logistic Regression | **0.9585** | 0.9701 | 0.0113 | 0.0095 | EXACT MATCH ✓ |

---

## 🧮 4. MODALITY ATTRIBUTION METHODOLOGY AUDIT

### Mathematical Formulation
Modality attribution percentages for the tri-modal pathway (`C+W+G`) were extracted from the fitted Logistic Regression meta-learners. 

For each disease estimator $d \in \{\text{T2D, PreDM, Obesity, MetSyn, NAFLD}\}$, the meta-learner fits 15 linear coefficients $w_{m, j}$ corresponding to the 5 disease probability features from each of the 3 modalities $m \in \{\text{Clinical, Wearable, Gut}\}$.

The raw modality importance weight $W_m(d)$ is defined as the sum of absolute coefficients for modality $m$:
$$W_m(d) = \sum_{j=1}^{5} |w_{m, j}^{(d)}|$$

The relative attribution percentage $A_m(d)$ is obtained by normalizing to 100%:
$$A_m(d) = \frac{W_m(d)}{\sum_{m'} W_{m'}(d)} \times 100\%$$

### Empirical Attribution Values (`C+W+G` Pathway)
```txt
• Type 2 Diabetes:      Clinical = 54.8%,  Wearable = 32.3%,  Gut = 12.9%
• Prediabetes:         Clinical = 69.9%,  Wearable = 18.6%,  Gut = 11.5%
• Obesity:             Clinical = 69.7%,  Wearable = 15.8%,  Gut = 14.5%
• Metabolic Syndrome:  Clinical = 66.4%,  Wearable = 10.1%,  Gut = 23.5%
• NAFLD:               Clinical = 44.1%,  Wearable = 12.3%,  Gut = 43.6%
```

### Critical Scientific Definition
> [!WARNING]
> **MODEL DECISION WEIGHTS — NOT BIOLOGICAL CAUSALITY**  
> These attribution percentages represent **linear decision boundary weights** of probability features inside the meta-learner model. They reflect how much weight the meta-learner places on each expert's probability output to minimize loss on this synthetic dataset. They MUST NOT be interpreted as causal or biological contributions to disease etiology.

---

## 🎛️ 5. CALIBRATION & THRESHOLDS VERIFICATION

| Pathway | T2D Threshold | PreDM Threshold | Obesity Threshold | MetSyn Threshold | NAFLD Threshold | Calibration Method |
|---|---|---|---|---|---|---|
| **C** | 0.1000 | 0.1000 | 0.1000 | 0.4100 | 0.4300 | Platt Sigmoid ✓ |
| **W** | 0.5200 | 0.4600 | 0.4500 | 0.3700 | 0.3700 | Platt Sigmoid ✓ |
| **G** | 0.3400 | 0.2900 | 0.3400 | 0.2600 | 0.3200 | Platt Sigmoid ✓ |
| **C+W** | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 0.1900 | Platt Sigmoid ✓ |
| **C+G** | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 0.1300 | Platt Sigmoid ✓ |
| **W+G** | 0.2200 | 0.1400 | 0.2100 | 0.3300 | 0.3400 | Platt Sigmoid ✓ |
| **C+W+G** | 0.1000 | 0.1000 | 0.1000 | 0.1500 | 0.1400 | Platt Sigmoid ✓ |

All calibrators and thresholds were fit exclusively on Validation data (`Split == 'val'`).

---

## ⚡ 6. ADAPTIVE ROUTING VERIFICATION

The `adaptive_router.py` module was tested against all 7 input combinations:
- `C` payload $\rightarrow$ Routed to `C` model
- `W` payload $\rightarrow$ Routed to `W` model
- `G` payload $\rightarrow$ Routed to `G` model
- `C+W` payload $\rightarrow$ Routed to `C+W` model
- `C+G` payload $\rightarrow$ Routed to `C+G` model
- `W+G` payload $\rightarrow$ Routed to `W+G` model
- `C+W+G` payload $\rightarrow$ Routed to `C+W+G` model

### Verification Checks:
- **Zero Zero-Padding**: Missing modalities are NOT filled with arbitrary zeros.
- **Zero Data Fabrication**: Missing modalities do NOT generate fake probability estimates.
- **Strict Pathway Isolation**: Every pathway uses its own pre-trained, calibrated meta-learner.

---

## 🔬 7. SCIENTIFIC INTERPRETATION OF FUSION RESULTS

1. **Clinical Biomarker Dominance**: Clinical lab biomarkers remain the single strongest predictive modality across all disease targets due to direct diagnostic criteria.
2. **Tri-Modal Macro F1 Equivalence**: Tri-modal fusion (`C+W+G` Macro F1 = **0.9585**) does not improve Macro F1 over Clinical alone (`C` Macro F1 = **0.9602**) because Clinical performance is near ceiling on synthetic diagnostic rules.
3. **Non-Clinical Telemedicine Synergy (`W+G`)**: In the absence of Clinical lab reports, fusing Wearable telemetry and Gut Microbiome data (**`W+G`**) achieves an **observed point-estimate improvement in Macro F1 to 0.8405** (vs. Wearable `W` = 0.8300 and Gut `G` = 0.6640). *(Note: Reflected as observed test-set point estimates without asserting unverified formal hypothesis tests).*
4. **NAFLD ROC-AUC Synergy (`C+G`)**: Fusing Gut Microbiome data with Clinical labs (**`C+G`**) increases NAFLD ROC-AUC from **0.9580** to **0.9701**, matching the high gut attribution weight (43.6%).
5. **Synthetic Data Scope**: All results apply strictly to this synthetic multimodal benchmark distribution and do not constitute evidence of real-world clinical efficacy.

---

## 📂 8. FINAL ARTIFACT INTEGRITY CHECK (`fusion_v1`)

```
fusion_engine/saved_models/fusion_v1/
├── meta_learners/
│   ├── C.joblib
│   ├── W.joblib
│   ├── G.joblib
│   ├── C+W.joblib
│   ├── C+G.joblib
│   ├── W+G.joblib
│   └── C+W+G.joblib
├── thresholds.json
├── calibrators.pkl
├── metrics.json
├── training_config.json
└── metadata.json
```
All files are frozen, validated, and reproducibly loadable.

---

## 🚀 9. GO / NO-GO RECOMMENDATION FOR PHASE 5

> [!IMPORTANT]
> **GO RECOMMENDATION FOR PHASE 5 (MEDICAL RAG & PLATFORM UI)**  
> `fusion_v1` is 100% leak-free, reproducibly frozen, scientifically framed, and validated across all 7 modality pathways.  
> The core AI pipeline (IMDIE + Experts + Fusion) is complete. We are ready to proceed to Phase 5 upon user approval.
